UTI Antibiotic Choices and Durations: Cystitis, Pyelonephritis, Men, Pregnancy and Recurrence

UTI treatment on the NP exam is a matching exercise: identify where the infection is and who the patient is, then pick the agent and the number of days that go with that combination. For acute cystitis in a nonpregnant woman, nitrofurantoin for 5 days, trimethoprim-sulfamethoxazole for 3 days where resistance is low, single-dose fosfomycin, or pivmecillinam are first line. Pyelonephritis and any infection with systemic features count as complicated under the 2025 IDSA guideline, which shortens treatment to 5 to 7 days of a fluoroquinolone or 7 days of another active agent for patients who are improving, while pregnancy, men and recurrence each change the rules on cultures, drugs and duration.

Assessment: locate the infection first

The 2025 IDSA complicated UTI guideline reframes the old split. A UTI confined to the bladder is localized (the AUA now uses the same word in place of "uncomplicated"). A UTI with features that suggest extension beyond the bladder is complicated: fever, chills or rigors, flank pain, costovertebral angle tenderness, signs of sepsis, or pelvic or perineal pain in men suggesting prostatitis. UTIs associated with an indwelling catheter, nephrostomy or stent, or with upper tract obstruction, are also complicated. Diabetes, immunocompromise or a urologic abnormality alone do not make an infection complicated.

Key history and examination points:

• Dysuria, frequency, urgency and suprapubic pain with no vaginal discharge or irritation point to cystitis. Vaginal symptoms raise vaginitis or a sexually transmitted infection.
• Fever, flank pain, nausea or vomiting, or CVA tenderness point to pyelonephritis.
• Pregnancy status for every woman of reproductive potential.
• Antibiotic use and urine cultures in recent months, which predict resistance.
• In older adults, nonspecific changes such as confusion or falls without urinary symptoms or fever are not, by themselves, evidence of UTI.

Testing: a urinalysis or dipstick (leukocyte esterase, nitrite) supports the diagnosis. Culture with susceptibility testing is not needed for a typical first episode of cystitis in a nonpregnant woman, but is needed for pyelonephritis, men, pregnancy, recurrent infection, treatment failure and atypical presentations.

Acute cystitis in nonpregnant women: IDSA first-line agents

Second-line options when first-line agents cannot be used: oral beta-lactams such as amoxicillin-clavulanate, cefpodoxime, cefdinir or cefaclor for 3 to 7 days, which are less effective. Fluoroquinolones (ciprofloxacin or levofloxacin for 3 days) work well but are reserved for situations where other agents cannot be used, because of collateral resistance and serious adverse effects. Amoxicillin or ampicillin alone are not used empirically because of high resistance.

Phenazopyridine for one to two days can relieve dysuria; it colors urine orange and does not treat infection.

Pyelonephritis and other complicated UTI

Outpatient management is reasonable for a patient who is not septic, can take oral medication and fluids, is not pregnant, and has reliable follow-up. Obtain a urine culture before the first dose.

The 2025 IDSA guideline builds empiric choice in steps: assess severity (sepsis or not), avoid agents that previous cultures showed to be resistant or that the patient received recently (avoid a fluoroquinolone if one was used in the past 12 months), consider allergies and interactions, and use the local antibiogram in sepsis. For oral therapy, fluoroquinolones and trimethoprim-sulfamethoxazole have the strongest data. Amoxicillin-clavulanate and oral cephalosporins may be appropriate in selected cases but are less studied.

Durations count from the first day of effective therapy. Nitrofurantoin and oral fosfomycin are generally not appropriate for complicated UTI.

UTI in men

• Always obtain a urine culture, and consider sexually transmitted infection testing in younger sexually active men.
• Afebrile men with symptoms limited to the bladder: a randomized trial in afebrile men treated with ciprofloxacin or trimethoprim-sulfamethoxazole found 7 days noninferior to 14 days. Seven days is the usual answer.
• Febrile UTI, flank pain or systemic symptoms in a man is complicated: 5 to 7 days of a fluoroquinolone or 7 days of another active agent once improving, per the 2025 IDSA guideline.
• Suspected acute bacterial prostatitis (fever, perineal pain, tender boggy prostate) may need 10 to 14 days or longer; the 2025 guideline notes the evidence is limited. Avoid vigorous prostatic massage.
• Recurrent UTI in men, or UTI with retention or hematuria that persists after treatment, warrants urologic evaluation.

Pregnancy

Untreated bacteriuria in pregnancy raises the risk of pyelonephritis, so pregnancy reverses the usual rule about asymptomatic bacteriuria.

• Screen with a urine culture early in pregnancy, typically at the first prenatal visit, and treat asymptomatic bacteriuria. IDSA 2019 suggests 4 to 7 days for asymptomatic bacteriuria in pregnancy.
• Agents commonly used for bacteriuria and cystitis: cephalexin, amoxicillin-clavulanate, fosfomycin, or nitrofurantoin. ACOG has long advised using nitrofurantoin and trimethoprim-sulfamethoxazole in the first trimester only when suitable alternatives are unlikely to work; confirm the current wording and durations in the 2023 ACOG clinical consensus. Culture results guide the final choice.
• Avoid fluoroquinolones and tetracyclines.
• Repeat a culture after treatment to document cure, and consider suppressive therapy after recurrent bacteriuria or pyelonephritis.
• Pyelonephritis in pregnancy is managed with hospital admission and parenteral beta-lactam therapy in most guidance, not outpatient oral therapy.

Asymptomatic bacteriuria outside pregnancy

IDSA 2019 recommends against screening for or treating asymptomatic bacteriuria in nonpregnant women, older adults in the community or long-term care, people with diabetes, people with spinal cord injury, and patients with catheters. Exceptions are pregnancy and planned endourologic procedures that breach the mucosa. In an older adult with delirium and bacteriuria but no fever or urinary symptoms, the guideline favors looking for other causes and observing, rather than reflexively treating.

Recurrent UTI in women: AUA/CUA/SUFU guideline

The guideline also advises against treating asymptomatic bacteriuria in women with recurrent UTI and against surveillance cultures in asymptomatic patients, and asks clinicians to look for alternative causes when symptoms persist after microbiological cure.

Monitoring, follow-up and referral triggers

• Cystitis: no test of cure in nonpregnant women whose symptoms resolve. Culture if symptoms persist at 48 to 72 hours or recur within weeks, and switch to an agent from a different class.
• Pyelonephritis: expect clinical improvement within 48 to 72 hours. Persistent fever or flank pain at 72 hours calls for imaging (ultrasound or CT) to look for obstruction or abscess.
• Admission or emergency referral: sepsis or hemodynamic instability, inability to tolerate oral therapy, pregnancy with pyelonephritis, suspected obstruction, or failure of outpatient therapy.
• Urology referral: recurrent infection in men, recurrent pyelonephritis, persistent hematuria after treatment, stones, gas-forming infection, or suspected anatomic abnormality.

Patient education

• Complete the prescribed course, even when symptoms settle in a day or two.
• Return for fever, flank pain, vomiting or symptoms that do not improve within 48 to 72 hours.
• Nitrofurantoin can darken urine; phenazopyridine turns urine orange and stains contact lenses.
• Fluoroquinolone counseling: tendon pain, numbness or palpitations need prompt review.
• For recurrence: hydration, cranberry products, vaginal estrogen after menopause, and the self-start plan with a culture first.

How the exam tests this

• Nitrofurantoin for pyelonephritis or fever. Always wrong.
• Fluoroquinolone for simple cystitis when first-line agents are available. Not first line.
• The 14-day reflex. Pyelonephritis improving on a fluoroquinolone needs 5 to 7 days, not 14; afebrile men need 7 days.
• Treating asymptomatic bacteriuria in an older adult or a patient with diabetes. Wrong, except in pregnancy.
• Missing the culture. Men, pregnancy, pyelonephritis and recurrence all need a culture before treatment.
• Trimethoprim-sulfamethoxazole despite a recent course or high local resistance.
• Pregnancy distractors: ciprofloxacin, doxycycline, or skipping the post-treatment culture.

Practice question

A 29-year-old nonpregnant woman has two days of fever to 38.7 C, right flank pain, nausea without vomiting, and dysuria. She is tolerating fluids, blood pressure is 118/72 mm Hg and heart rate 96. Right CVA tenderness is present. Urinalysis shows pyuria and nitrites. She took no antibiotics in the past year. Local fluoroquinolone resistance among Escherichia coli is 6 percent. A urine culture is sent. Which of the following is the most appropriate treatment?

• A. Nitrofurantoin 100 mg twice daily for 5 days.
• B. Ciprofloxacin 500 mg twice daily, planning a 7-day course if she improves.
• C. Fosfomycin 3 g as a single dose.
• D. Ciprofloxacin 500 mg twice daily for 14 days.

Answer: B. She has pyelonephritis without sepsis, tolerates oral intake, and lives where fluoroquinolone resistance is under 10 percent, so oral ciprofloxacin with a culture sent first is appropriate, and the 2025 IDSA guideline supports 5 to 7 days of a fluoroquinolone in a patient who is improving. Nitrofurantoin (A) and single-dose fosfomycin (C) do not achieve adequate renal tissue levels and are generally inappropriate for complicated UTI. A 14-day course (D) is the older duration that the 2025 guideline replaced, adding adverse effects and resistance pressure without benefit.

Key points

Related NPPace guides

• Asthma Step Therapy on the NP Exam: GINA Tracks, Stepping Up and Stepping Down
• COPD in Primary Care: GOLD Groups, Inhaler Choice and When to Add What
• Outpatient Community-Acquired Pneumonia: Who Goes Home, Which Antibiotic and Follow-Up
• How to Read a Primary-Care Vignette Like a Provider: The 5-Step Method
• AANP vs ANCC: Which NP Certification Exam Should You Take?